| Trial ID: | L0335 |
| Source ID: | NCT03950505
|
| Associated Drug: |
Nesinaact
|
| Title: |
To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Steatohepatitis|Type2 Diabetes
|
| Interventions: |
Drug: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
|
| Outcome Measures: |
A degree of liver steatosis|A degree of liver fibrosis|Clinical glucometabolic parameters : HbA1c|Clinical glucometabolic parameters : Lipid parameters|Clinical glucometabolic parameters : Liver enzymes|Clinical glucometabolic parameters :Anthropometric parameters
|
| Sponsor/Collaborators: |
Yonsei University
|
| Gender: |
All
|
| Age: |
20 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
60
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
May 29, 2020
|
| Completion Date: |
December 2020
|
| Results First Posted: |
--
|
| Last Update Posted: |
October 9, 2020
|
| Locations: |
Division of Geriatrics, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
|
| URL: |
https://ClinicalTrials.gov/show/NCT03950505
|
